The Senate Banking Committee advanced a landmark digital asset market structure bill after months of negotiations, signaling fresh momentum for the measure.
The industry framing of “what can AI do?” is mismatched with how AI is deployed today, and the conclusions can leave firms a tax season behind their peers.
Degron Therapeutics will have stiff competition in immunology, as Novartis inked a $5.7 billion agreement with Monte Rosa Therapeutics last year to develop molecular glues for undisclosed immune-mediated conditions.
While Takeda is eliminating 4,500 roles across its global operations, the company has some 2,200 jobs currently open for hiring, for which internal candidates will be prioritized.